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Colony-Stimulating Factor-1 Suppresses Responses to CpG
DNA and Expression of Toll-Like Receptor 9 but Enhances
Responses to Lipopolysaccharide in Murine Macrophages1
Matthew J. Sweet,2*† Carol C. Campbell,* David P. Sester,† Damo Xu,* Rebecca C. McDonald,†
Katryn J. Stacey,† David A. Hume,† and Foo Y. Liew*
During bacterial infections, the balance between resolution of infection and development of sepsis is dependent upon the macro-
phage response to bacterial products. We show that priming of murine bone marrow-derived macrophages (BMMs) with CSF-1
differentially regulates the response to two such stimuli, LPS and immunostimulatory (CpG) DNA. CSF-1 pretreatment enhanced
IL-6, IL-12, and TNF- production in response to LPS but suppressed the same response to CpG DNA. CSF-1 also regulated
cytokine gene expression in response to CpG DNA and LPS; CpG DNA-induced IL-12 p40, IL-12 p35, and TNF- mRNAs were
all suppressed by CSF-1 pretreatment. CSF-1 pretreatment enhanced LPS-induced IL-12 p40 mRNA but not TNF- and IL-12
p35 mRNAs, suggesting that part of the priming effect is posttranscriptional. CSF-1 pretreatment also suppressed CpG DNA-
induced nuclear translocation of NF-B and phosphorylation of the mitogen-activated protein kinases p38 and extracellular
signal-related kinases-1/2 in BMMs, indicating that early events in CpG DNA signaling were regulated by CSF-1. Expression of
Toll-like receptor (TLR)9, which is necessary for responses to CpG DNA, was markedly suppressed by CSF-1 in both BMMs and
thioglycolate-elicited peritoneal macrophages. CSF-1 also down-regulated expression of TLR1, TLR2, and TLR6, but not the LPS
receptor, TLR4, or TLR5. Hence, CSF-1 may regulate host responses to pathogens through modulation of TLR expression.
Furthermore, these results suggest that CSF-1 and CSF-1R antagonists may enhance the efficacy of CpG DNA in vivo. The
Journal of Immunology, 2002, 168: 392–399.
T he ability of the host to respond to a bacterial challenge isconferred by cells of the innate immune system, whichdetect bacterial products such as LPS, CpG DNA, pepti-
doglycan, and bacterial lipoproteins (1). Recognition of these
products by macrophages results in secretion of cytokines and
small molecules that mediate the inflammatory response. Both the
site of challenge and the magnitude of the response dictate out-
come; local infections trigger a controlled response in which the
infection is contained and resolved, whereas systemic infection can
lead to dysregulated cytokine production that can ultimately result
in multiple organ failure and mortality. Although the effects of
LPS and CpG DNA on macrophages are very similar, their toxic-
ities in mice differ greatly: LPS is highly toxic (2, 3), whereas CpG
DNA alone is not toxic (4), unless administered to D-galac-
tosamine-sensitized mice (5). This important difference has a ma-
jor implication for the therapeutic potential of CpG DNA. How-
ever, the reason for this difference is still unclear.
Toll-like receptors (TLRs)3 are an evolutionarily conserved
family that share homology with the IL-1R family in the cytoplas-
mic domain. Mammalian TLRs are critical in instigating responses
to bacterial products. C3H/HeJ LPS nonresponder mice contain an
inactivating point mutation in the TLR4 gene (6, 7), and TLR4-
deficient mice do not produce inflammatory cytokines in response
to LPS (8). TLR2-deficient mice are still LPS responsive but fail
to respond to bacterial lipoproteins or peptidoglycan (9), and
TLR9-deficient mice are incapable of responding to CpG-contain-
ing DNA (10). Engagement of TLRs triggers signaling through at
least NF-B and the mitogen-activated protein kinase (MAPK)
family members, extracellular signal-related kinase (ERK)-1 and
-2, p38, and c-Jun N-terminal kinase, and results in transcription of
proinflammatory genes (1, 11).
The macrophage response to bacterial products is also regulated
by a variety of endogenous cytokines. Both IFN- and GM-CSF
(primarily T cell products) can prime the inflammatory response,
whereas IL-4, IL-10, and TGF- are able to suppress macrophage
activation. CSF-1, a cytokine that regulates growth, differentiation,
and function of macrophages, is readily detectable in peripheral
blood in the steady state and is further induced in vivo after in-
fection (12) or challenge with LPS (13). Priming of macrophages
with CSF-1 can enhance LPS-induced IL-1, IL-6, and TNF- pro-
duction (14). CSF-1 treatment in vivo increased levels of LPS-
induced TNF- and IL-6 (15), and CSF-1-deficient op/op mice
have enhanced resistance to LPS shock (16). Furthermore, CSF-1
primed human monocytes for enhanced responses to LPS (17).
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These effects of CSF-1 might be due to regulation of LPS recog-
nition via the CD14-TLR4-MD2 complex or at subsequent levels
(MyD88, TNFR-associated factor 6, IL-1R-associated kinase) that
appear to be shared with other microbial agonists such as CpG
DNA (18, 19). To distinguish these alternatives, we compared the
effect of CSF-1 on the response to LPS and CpG DNA in primary
murine bone marrow-derived macrophages (BMMs). We report in
this work that CSF-1 enhanced macrophage responses to LPS but
suppressed expression of TLR9 and responses to CpG DNA. These
findings provide a mechanism for the differential cytotoxic effect
of LPS and CpG DNA and may lead to novel therapeutic strategies
against bacteria-induced shock.
Materials and Methods
Cell culture and reagents
RPMI 1640 medium (Life Technologies, Paisley, U.K.) containing 10%
FCS, penicillin/streptomycin, and glutamine (complete medium) was used
for culture of BMMs. BMMs were derived from the femurs of adult
BALB/c mice (Harlan Olac, Bichester, U.K.). In some experiments, adult
CD1 outbred mice were used for preparation of BMMs with similar results.
Briefly, femurs were flushed with complete medium and bone marrow cells
were plated out in complete medium containing 104 U/ml (100 ng/ml)
recombinant human CSF-1 (a gift from Chiron, Emeryville, CA) on 10-cm
bacteriological plastic plates (Bibby Sterilin, Staffordshire, U.K.) for 7 days
in a 37°C incubator containing 5% CO2. Thioglycolate-elicited peritoneal
macrophages (TEPMs) were obtained by injecting BALB/c mice i.p. with
1 ml of 10% thioglycolate broth followed by peritoneal lavage with 10 ml
of PBS 5 days later. LPS from Salmonella minnesota (Sigma-Aldrich, St.
Louis, MO) was used at a final concentration of 100 ng/ml in all cell culture
experiments. The synthetic tripalmitoylated lipopeptide Pam3CysSerLys4
(Roche, Basel, Switzerland) was used at a final concentration of 10 ng/ml
in cell culture. Phosphodiester oligodeoxynucleotides (Sigma-Genosys,
Cambridge, U.K.) were used at a final concentration of 3 M in cell cul-
ture. Oligodeoxynucleotides used were activating oligonucleotide-1
(AO-1) (5-GCTCATGACGTTCCTGATGCTG-3) and nonactivating oli-
gonucleotide-1 (NAO-1) (5-GCTCATGAGCTTCCTGATGCTG-3)
(20). IL-3 (a gift from Dr. A. Hapel, Australian National University, Can-
berra, Australia) stored at a concentration of 104 U/ml at 20°C was used
at 103 U/ml in cell culture. PMA (Sigma-Aldrich) was stored as a stock
solution (10 mg/ml) in DMSO at 70°C and used at a final concentration
of 100 ng/ml.
In vitro treatment of cells and ELISAs
For all in vitro experiments, BMMs were plated out in 24-well plates at 5
105 cells per well in 1 ml of complete medium with or without CSF-1 (104
U/ml) overnight. The next morning, cells were stimulated with 100 ng/ml
LPS, 3 M CpG-containing oligonucleotide (AO-1), 3 M control oligo-
nucleotide (NAO-1), 10 ng/ml Pam3CysSerLys4, or medium. After 24 h
(unless otherwise stated), supernatants were collected and stored at 20°C
until ELISAs were performed. ELISAs were conducted using paired Abs
(BD PharMingen, San Diego, CA).
Immunoblotting
BMMs (2  106) were plated on 60-mm dishes (Corning Life Sciences,
Acton, MA) in 5 ml of medium or 5 ml of medium plus CSF-1 (105 U/ml)
for 18 h. Culture medium was reduced to 2 ml and cells were treated as
described in the figures. Cell monolayers were lysed with boiling 66 mM
Tris-Cl (pH 7.4)/2% SDS/1 mM sodium vanadate/1 mM sodium pyrophos-
phate/1 mM sodium molybdate/10 mM sodium fluoride. Equal amounts of
total protein in cell extracts were resolved by SDS-PAGE with 10% poly-
acrylamide seperating gels, transferred to Immobilon-P (Millipore, North
Ryde, New South Wales, Australia), blocked, and probed with the anti-
phospho p42/p44 MAPK rabbit polyclonal Ab (1:1000) (New England
Biolabs, Beverly, MA), washed, and incubated with HRP-linked anti-rabbit
IgG (1:2000) (New England Biolabs). Blots were washed and detected
using ECL Plus reagents (Amersham Pharmacia Biotech, Piscataway, NJ)
and Hyperfilm-ECL (Amersham Pharmacia Biotech). Membranes were
then sequentially stripped with 63 mM Tris-Cl (pH 6.7)/2% SDS/100 mM
2-ME and reprobed with rabbit anti-phospho p38 (New England Biolabs),
rabbit anti-p42/p44 MAPK (New England Biolabs), and rabbit anti-p38
(New England Biolabs).
Nuclear extract preparation and gel shift assays
The methods used for preparation of nuclear extracts and gel shift assays
have been described previously (21). For nuclear extract production,
BMMs were pretreated overnight with medium or CSF-1 (5  104 U/ml)
and then stimulated for 45 min with AO-1 (0.3 M) or LPS (10 ng/ml). For
gel shift assays, a double-stranded oligonucleotide corresponding to an
NF-B site from the murine TNF- promoter (5-CAAACAGGGGGCTT
TCCCTCCTC-3) (21) was end-labeled with [-32P]ATP using polynucle-
otide kinase and separated on a NAP-5 column (Amersham Pharmacia
Biotech).
Total RNA isolation and quantitative PCR
Total RNA was prepared using RNAzol B (Biogenesis, Poole, U.K.) ac-
cording to the manufacturer’s instructions. RNA was treated with DNase 1
(Ambion, Austin, TX) and reverse transcribed to cDNA using Superscript
reverse transcriptase (Life Technologies). Negative control samples (no
first strand synthesis) were prepared by performing reverse transcription
reactions in the absence of reverse transcriptase. cDNA levels of murine
IL-12 (p40), IL-12 (p35), TNF-, hypoxanthine phosphoribosyl transferase
(HPRT), TLR1, TLR2, TLR4, TLR5, TLR6, and TLR9 were quantitated
by real-time PCR using an ABI Prism 7700 sequence detector (Applied
Biosystems, Foster City, CA) according to the manufacturer’s instructions.
Amplification was achieved using an initial cycle of 50°C for 2 min and
95°C for 10 min, followed by 40 cycles of 95°C for 15 s and 50°C for 1
min. cDNA levels during the linear phase of amplification were normalized
against HPRT controls. Determinations were made in triplicate and
mean  SD was determined. Primers (f, forward; r, reverse) and 5-6-
carboxy-fluorescein-labeled/3-6-carboxy-tetramethyl-rhodamine-labeled
probes (p) used to detect expression of the corresponding murine genes
were as follows: IL-12 (p40) (f, 5-GGAATTTGGTCCACTGAAATTT
TAAA-3; r, 5-CACGTGAACCGTCCGGAGTA-3; p, 5-ACAAGAC
TTTCCTGAAGTGTGAAGCACCAAAT-3); IL-12 (p35) (f, 5-AAGA
CATCACACGGGACCAAA-3; r, 5-CAGGCAACTCTCGTTCTTGTG
TA-3; p, 5-CAGCACATTGAAGACCTGTTTACCACTGGA-3); TNF-
(Applied Biosystems); TLR1 (f, 5-TGGATGTGTCCGTCAGCACTA-3; r,
5-AGAGCAGCCCTGGTCTTCAA-3; p, 5-CACACACTTGATGTTAGA
CAGTTCCAAACCGAT-3); TLR2 (f, 5-AAGATGCGCTTCCTGAAT
TTG-3; r, 5-TCCAGCGTCTGAGGAATGC-3; p, 5-CGTTTTTACCA
CCCGGATCCCTGTACTG-3); TLR4 (f, 5-AGGAAGTTTCTCTGGA
CTAACAAGTTTAGA-3; r, 5-AAATTGTGAGCCACATTGAGTTTC-
3; p, 5-GCCAATTTTGTCTCCACAGCCACCA-3); TLR5 (f, 5-GCA
CGAGGCTTCTGCTTCA-3; r, 5-GCATCCAGGTGTTTGAGCAA-3;
p, 5-CATTCTGTGCCCATTCAAAGTCTTTGCTG-3); TLR6 (f, 5-
CTCGGAGACAGCACTGAAGTCA-3; r, 5-CGAGTATAGCGCCTCC
TTTGAA-3; p, 5-ATGATAGAGCACGTCAAAAACCAAGTGTTCCT
C-3); TLR9 (f, 5-AGGCTGTCAATGGCTCTCAGTT-3; r, 5-TGAA
CGATTTCCAGTGGTACAAGT-3; p, 5-TGCCGCTGACTAATCTGC
AGGTGCT-3); HPRT (f, 5-GCAGTACAGCCCCAAAATGG-3; r, 5-
AACAAAGTCTGGCCTGTATCCAA-3; p, 5-TAAGGTTGCAAGCTT
GCTGGTGAAAAGGA-3).
PCR/Southern hybridization
Total RNA was treated with DNase 1 (Ambion), reverse transcribed to
cDNA using Superscript reverse transcriptase (Life Technologies), and
used as a template for semiquantitative PCR. No reverse-transcriptase neg-
ative controls were performed for all samples. Primers used were as fol-
lows: TLR9 (f, 5-CTACAACAGCCAGCCCTTTA-3, r, 5-GCTGAG
GTTGACCTCTTTCA-3); TLR4 (f, 5-AGAGAATCTGGTGGCTGT
GG-3; r, 5-TCAACCGATGGACGTGTAAA-3); and HPRT (f, 5-
GTTGGATACAGGCCAGACTTTGTTG-3; r, 5-GAGGGTAGGCTGG
CCTATAGGCT-3). PCR cycling conditions were as follows: 94°C for
30 s, 54°C for 30 s, 72°C for 60 s (21 cycles for HPRT, 21 cycles for TLR4,
21 cycles for TLR9 with BMM cDNA, or 24 cycles for TLR9 with TEPM
cDNA). PCR products were separated on 1.8% agarose gels, transferred to
zetaprobe nylon membrane (Bio-Rad, Hercules, CA), and subjected to
Southern hybridization using cDNA probes for TLR9, TLR4, and HPRT.
Probes were labeled by random priming (Amersham Pharmacia Biotech).
Results
Differential effects of CSF-1 on LPS- and CpG DNA-induced
cytokine production from BMMs
To compare the effects of CSF-1 on macrophage responses to LPS
and CpG DNA, we used primary BMMs, which respond well to
both agents (20), and measured production of inflammatory cyto-
kines by ELISA. Fig. 1 demonstrates that overnight pretreatment
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of BMMs with CSF-1 enhanced levels of LPS-induced IL-6, IL-
12, and TNF- protein release into the medium by 15-, 72-, and
6-fold, respectively. In direct contrast, CSF-1 pretreatment sup-
pressed CpG DNA-induced IL-6, IL-12, and TNF- by 10-, 8-,
and 7-fold, respectively. We analyzed the effect of CSF-1 on CpG
DNA responses in more detail. Fig. 2A shows that CSF-1 down-
regulated induction of IL-6 by CpG DNA in BMMs over a con-
centration range, whereas Fig. 2B shows that this effect was ap-
parent over the length of a 24-h time course. Because IFN- can
prime macrophage responses to both LPS and CpG DNA (21, 22),
we assessed whether IFN- could overcome the suppressive effect
of CSF-1 on the DNA response. As expected, IFN- pretreatment
enhanced levels of LPS-induced IL-6 and IL-12 in BMMs (Fig. 3).
This priming effect was not as striking in CSF-1-pretreated mac-
rophages, suggesting that CSF-1 and IFN- might provide similar
priming signals. Levels of CpG DNA-induced IL-6 and IL-12 were
also enhanced by IFN- priming, but priming with IFN- did not
overcome the suppressive effect of CSF-1 on the CpG DNA re-
sponse (Fig. 3).
Next we assessed whether the effect of CSF-1 on LPS and CpG
DNA responses was selective to CSF-1 or was a manifestation of
its growth-stimulating activity. IL-3 and PMA can both trigger
BMM proliferation (23, 24), and IL-3 is known to prime macro-
phage responses to LPS (25, 26). Therefore, IL-3, PMA, and
CSF-1 were compared for their ability to regulate IL-6 production
in response to LPS and CpG DNA. Fig. 4 shows that only CSF-1
was able to enhance the LPS response and suppress the CpG DNA
response. IL-3 pretreatment primed responses to both LPS and
CpG DNA, whereas PMA did not affect the LPS response but
suppressed the CpG DNA response slightly (1.5- to 2-fold). Hence,
the ability of CSF-1 to enhance LPS responses and suppress CpG
DNA responses is unlikely to be related to its ability to trigger
macrophage proliferation.
Regulation of LPS- and CpG DNA-induced TNF- and IL-12
mRNA by CSF-1
To determine the level at which CSF-1 differentially regulates the
LPS and CpG DNA response, we assessed mRNA levels of IL-12
p40 and p35 and TNF- in response to LPS and CpG DNA with
or without CSF-1 priming (Fig. 5). Priming with CSF-1 enhanced
LPS-induced IL-12 (p40) mRNA levels at 4 h by 10 fold but did
not alter LPS-induced IL-12 (p35) and TNF- mRNAs. Whereas
CSF-1 was selective in priming LPS-induced cytokine mRNAs,
levels of IL-12 (p40), IL-12 (p35), and TNF- after 4 h of CpG
DNA were all suppressed by priming with CSF-1 (6-, 4.5-, and
3-fold, respectively). This suppressive effect was also apparent at
2 h post-CpG DNA treatment (data not shown).
Effect of CSF-1 on LPS-induced and CpG DNA-induced NF-B,
p38, and ERK-1/2 MAPK activation
NF-B and p38 MAPK activation are early events in triggering
both LPS and CpG DNA-induced gene expression (21, 27–29).
Nuclear translocation of NF-B in response to CpG DNA but not
LPS was inhibited by CSF-1 pretreatment (Fig. 6A). Similarly,
phosphorylation of p38 in response to CpG DNA was suppressed
by pretreatment with CSF-1 from the earliest time point examined
(Fig. 6B). To determine whether CSF-1 altered the ligand dose-
response curve (sensitivity) or the maximal response, the effect of
FIGURE 1. Effect of CSF-1 on BMM responses to LPS and CpG DNA.
BMMs were pretreated with CSF-1 (104 U/ml) or were left untreated over-
night. The next morning, cells were treated with medium, LPS (100 ng/ml),
AO-1 (3 M), or NAO-1 (3 M) for 24 h. IL-12, IL-6, and TNF- levels
in supernatants were assayed by ELISA. Data are mean of triplicates SD.
IL-6 was not detected in supernatants from control- or NAO-1-treated cells.
Similar results were obtained in six independent experiments.
FIGURE 2. Effect of CSF-1 on dose response and time course of CpG
DNA-induced IL-6 production. A, BMMs were pretreated overnight with
medium or CSF-1 (5  104 U/ml) and stimulated the next day with the
indicated concentrations of AO-1 for 24 h, and IL-6 levels were deter-
mined. Data points represent the mean of triplicates  SD, and similar
results were obtained in two independent experiments. B, BMMs were
pretreated overnight with CSF-1 (104 U/ml) and were stimulated the next
day with AO-1 (3 M) for the period indicated. IL-6 levels were estimated
by ELISA (mean of triplicates  SD).
394 CSF-1 AND MACROPHAGE RESPONSES TO CpG DNA AND LPS
 by guest on January 23, 2014
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
CSF-1 pretreatment on p38 phosphorylation over a range of CpG
DNA doses was determined at 30 min poststimulation. Fig. 7A
demonstrates that 10-fold higher concentrations of CpG DNA
were required to induce p38 phosphorylation in CSF-1-pretreated
cells. In contrast, LPS-induced p38 phosphorylation was not affected
by CSF-1 pretreatment (Fig. 7B), indicating that enhancement of LPS
responses by CSF-1 occurred independently of p38 activation. Phos-
phorylation of ERK-1/2 is also triggered by LPS and CpG DNA in
BMMs (20), and we assessed the effect of CSF-1 pretreatment on
CpG DNA- and LPS-triggered ERK-1 and -2 phosphorylation (Fig.
7). Because CSF-1 itself triggers sustained phosphorylation of ERK-1
and -2 in BMMs (30), basal levels of phosphorylated ERK-1 and -2
were much higher in CSF-1-pretreated BMMs than in untreated
BMMs. Nonetheless, CSF-1 pretreatment blocked the ability of CpG
DNA to enhance levels of phosphorylated ERK-1 and -2 over the
concentration range examined (Fig. 7A), whereas LPS was still able to
activate ERK-1/2 even in the presence of CSF-1 (Fig. 7B). Further-
more, the extent of the LPS-mediated ERK-1/2 phosphorylation was
not altered by CSF-1 pretreatment, despite the elevated basal activa-
tion state (Fig. 7B). These data suggest that CSF-1 alters an early stage
FIGURE 4. Comparison of the effects of CSF-1, IL-3, and PMA on IL-6
production in response to LPS and CpG DNA. BMMs were pretreated with
CSF-1 (105 U/ml), IL-3 (1000 U/ml), or PMA (100 ng/ml), or were left
untreated overnight. The next morning, cells were treated with medium,
LPS (100 ng/ml), or AO-1 (3 M) for 24 h. IL-6 levels in supernatants
were assayed by ELISA. Results (mean of triplicates  SD) were ex-
pressed as fold increase compared with IL-6 levels in unprimed superna-
tants treated with LPS (1125  52 pg/ml) or AO-1 (331  49 pg/ml). IL-6
was not detectable in supernatants of cells primed with medium alone,
CSF-1, IL-3, or PMA and triggered with medium only (data not shown).
Similar results were obtained in two experiments.
FIGURE 5. Effect of CSF-1 pretreatment on LPS- and CpG DNA-in-
duced IL-12 (p40), IL-12 (p35), and TNF- mRNAs. BMMs, pretreated
overnight with CSF-1 (104 U/ml) or left untreated, were stimulated for 4 h
with LPS (100 ng/ml), AO-1 (3 M), or medium. Total cellular RNA was
isolated, cDNAs were prepared, and levels of IL-12 (p40), IL-12 (p35), and
TNF- mRNA relative to HPRT were estimated by quantitative PCR (n 
3  SD). Similar results were obtained in two independent experiments.
FIGURE 6. Effect of CSF-1 on CpG DNA-induced NF-B and p38
MAPK activation. A, BMMs were pretreated with medium or CSF-1 over-
night and were stimulated the next morning with AO-1 or LPS for 45 min.
Levels of NF-B in nuclear extracts were assessed by gel shift assay. B,
BMMs, pretreated overnight with medium or CSF-1, were stimulated with
AO-1 (3 M) for the time interval indicated. Cell extracts were prepared,
and phosphorylated p38 levels were assessed by Western blotting. Blots
were stripped and reprobed for total p38 as a loading control. Similar
results were obtained in two independent experiments.
FIGURE 3. IFN- does not overcome the inhibitory effect of CSF-1 on
CpG responses. BMMs were pretreated with CSF-1 (104 U/ml) or were left
untreated overnight. The next morning, appropriate wells were pretreated
with IFN- (50 U/ml) for 30 min before stimulation with LPS (100 ng/ml),
AO-1 (3 M), or NAO-1 (3 M). Supernatants were collected after 24 h,
and IL-6 and IL-12 levels were estimated by ELISA (values are mean of
triplicates  SD). IL-6 and IL-12 were not detected in supernatants from
control- or NAO-1-treated cells.
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of CpG DNA recognition but acts more distally to activate LPS
responses.
The effect of CSF-1 on expression of TLR family members
Mice deficient for TLR9 are unable to respond to CpG-containing
phosphorothioate DNA (10). Whether TLR9 is required for uptake
of DNA, directly recognizes CpG DNA, or lies downstream in the
recognition pathway is yet to be determined (31). The diminished
CpG responsiveness observed above hints at a reduction in recep-
tor expression or affinity in response to CSF-1. Therefore, we as-
sessed the effect of CSF-1 on expression of TLR9 mRNA in
BMMs. Indeed, CSF-1 treatment resulted in a 20-fold reduction in
TLR9 mRNA levels in BMMs (Fig. 8A). To assess the specificity
of this response, we examined the effect of CSF-1 on expression of
other TLR family members, because these receptors are instru-
mental in triggering cellular responses to other bacterial products,
including LPS, peptidoglycan, and bacterial lipoproteins. Over-
night treatment with CSF-1 did not significantly affect mRNA lev-
els of the LPS receptor TLR4 (Fig. 8B). Levels of TLR5 mRNA
were also unaffected by CSF-1, but mRNA levels of TLR1, TLR2,
and TLR6 were all suppressed by CSF-1 treatment (2.4-, 4.8-, and
4-fold, respectively). Hence, CSF-1 has a selective effect on ex-
pression of different TLR family members. The effect of CSF-1
was most pronounced on TLR9 expression (20-fold or greater re-
duction), but the moderate suppression of TLR2 and TLR6 mRNA
levels by CSF-1 (4- to 5-fold) implies that responses to bacterial
lipopeptides, peptidoglycan, and other TLR2 agonists might also
be modulated by CSF-1. Therefore, we tested the ability of CSF-1
to regulate IL-6 production from BMMs in response to a synthetic
lipopeptide, Pam3CysSerLys4, that is known to act through TLR2
(32). Fig. 8C shows that although CSF-1 pretreatment clearly sup-
pressed IL-6 production in response to CpG DNA, it had no effect
on the response to Pam3CysSerLys4. Hence, although CSF-1 can
down-regulate the level of TLR2 mRNA, the effect appears to be
insufficient to modulate IL-6 production in response to a TLR2
agonist.
Regulation of TLR9 expression in macrophages by CSF-1
Next, we analyzed the effect of other agents that cause BMM pro-
liferation on TLR9 expression. Levels of TLR9 mRNA were as-
sessed in BMMs treated overnight with medium, CSF-1, IL-3, or
PMA. Fig. 9A demonstrates that only CSF-1 was able to dramat-
ically regulate TLR9 expression; IL-3 did not alter levels of TLR9
mRNA, and PMA, which down-regulated CpG responses1.5- to
2-fold (Fig. 4), had a similar effect on TLR9 expression. To assess
the time course of CSF-1 down-regulation of TLR9 expression,
BMMs starved overnight of CSF-1 were treated with CSF-1 over
a 20-h time course. Maximal suppression of TLR9 expression oc-
curred between 4 and 8 h, and an effect was apparent by 1 h
post-CSF-1 (Fig. 9B).
Although the effects of CSF-1 on BMMs are clearly dissociated
from its growth-promoting effects, these cells are unusual in that
mature macrophages in vivo are generally not actively proliferat-
ing. Therefore, we analyzed the effect of CSF-1 on expression of
TLR9 in TEPMs, which are postmitotic. We have found that, al-
though freshly isolated TEPMs respond well to CpG DNA, they
rapidly lose responsiveness to CpG DNA but retain LPS responses
when cultured ex vivo on either tissue culture or bacterial plastic
(data not shown). In keeping with this pattern, TLR9 mRNA levels
were 20- to 50-fold less in cultured TEPMs than CSF-1-starved
BMMs (data not shown). Nonetheless, this low basal level of
TLR9 expression was still regulated by CSF-1. Overnight treat-
ment of TEPMs with CSF-1 further down-regulated expression of
TLR9 but did not alter levels of TLR4 compared with control cells
(Fig. 9C).
Discussion
LPS and CpG DNA have differing toxicities in vivo. Administra-
tion of LPS can lead to fever, shock, and multiorgan failure re-
sulting in death. There are no reports of toxicity of bacterial DNA
alone, although pretreatment of mice with Escherichia coli DNA
can enhance the toxicity of LPS in vivo (33), probably by the
induction of IFN-. Even phosphorothioate-stabilized CpG oligo-
nucleotides have minimal toxicity (4). The relative nontoxicity of
CpG DNA is an attractive feature for its use as a vaccine adjuvant
and for other therapeutic strategies.
Analysis of macrophage gene expression in vitro has suggested
that the differing toxicities of LPS and CpG DNA may be due to
both qualitative and quantitative differences in cytokine gene in-
duction. For example, CpG DNA was a relatively poor stimulus
for IL-1 (21), and LPS but not CpG DNA stimulated NO pro-
duction from macrophages without IFN- priming (21, 22). How-
ever, the situation in vivo is likely to be more complex due to the
presence of many other cytokines, which will modify the responses
to LPS and CpG DNA. Here, we have found that CSF-1, which is
present constitutively in vivo and is a macrophage growth and
survival factor, differentially affects the responses to LPS and CpG
DNA. In the presence of CSF-1, the LPS response was elevated
and the CpG DNA response suppressed so that LPS became
far more effective than CpG DNA at stimulating IL-6, IL-12,
and TNF- production from BMMs (62-, 27-, and 23-fold,
respectively).
FIGURE 7. Effect of CSF-1 pretreatment on CpG DNA- and LPS-induced MAPK p38 and ERK-1 and -2 phosphorylation. A, BMMs, pretreated
overnight with medium control or CSF-1, were stimulated with AO-1 over the concentration range indicated for 30 min. Cell lysates were prepared and
levels of phosphorylated p38, total p38, phosphorylated ERK-1/2, and total ERK-1/2 were assessed by Western blotting. B, BMMs, pretreated overnight
with medium control or CSF-1, were stimulated with a range of LPS concentrations for 30 min. Extracts were analyzed as in A. Similar results were obtained
in two independent experiments.
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The ability of CSF-1 to selectively enhance the LPS and sup-
press the CpG DNA response of BMMs is unlikely to be related to
its activity as a growth factor. IL-3 and PMA did not have selective
effects on LPS and CpG DNA responses; IL-3 pretreatment primed
BMMs for enhanced IL-6 production in response to both LPS and
CpG DNA, whereas PMA pretreatment did not have significant
effects on LPS-induced IL-6 and modestly suppressed CpG DNA-
induced IL-6 synthesis. Furthermore, IL-3 and PMA had little ef-
fect on TLR9 expression, whereas CSF-1 markedly suppressed
expression of this molecule. IL-3 was actually more effective at
priming CpG DNA responses than LPS responses. Although the
ability of IL-3 to synergize with LPS for macrophage activation
has been documented (25, 26), its ability to regulate responses to
CpG DNA has not been reported. Given that CpG DNA drives
strong Th1 responses in vivo and that IL-3 is a product of activated
T cells, IL-3 may be involved in amplification of responses to CpG
DNA in vivo, as has been suggested for IFN- (22).
Because concentrations of CSF-1 are markedly and rapidly en-
hanced in serum, spleen, liver, lung, and kidney after LPS admin-
istration (13) and during infection (12, 34), macrophages recruited
to the site of infection during a bacterial challenge would be ex-
pected to have an impaired response to CpG DNA. The implica-
tions of this are not obvious, because the role of bacterial DNA in
an infection is not clear and will remain so until experiments using
bacterial infection models in TLR9 gene-targeted mice are per-
formed. Intact bacterial pathogens do not display their DNA, and
detection of CpG DNA during a bacterial challenge may imply that
the host has successfully destroyed the invading organism. In this
case, CSF-1 may be important in dampening down inappropriate
inflammatory responses to bacterial DNA. In contrast, both LPS
and CpG DNA rapidly down-regulate cell surface expression of
the CSF-1R in BMMs (20). Hence, macrophages present at the site
of infection will have already encountered bacterial cell wall prod-
ucts such as LPS and are unlikely to be CSF-1 responsive. Such
cells therefore may be hypersensitive to the effects of CpG DNA.
Consistent with this model, we have found that LPS and CpG
DNA can synergize for IL-6 and IL-12 production from BMMs
(data not shown).
TLR9 is an essential component of the DNA response (10), and
the ability of human and murine TLR9 to confer species-specific
responses to different CpG-containing phosphorothioate-stabilized
CpG oligonucleotides is suggestive of a role in direct recognition
(35). The expression of TLR9 was profoundly reduced by CSF-1,
which provides a clear explanation for the suppression of bacterial
DNA responses by CSF-1. CSF-1 also moderately suppressed
TLR1, 2, and 6 mRNA levels in BMMs, but surprisingly did not
FIGURE 8. Effect of CSF-1 on expression of TLRs in BMMs. A,
BMMs were treated overnight with medium or CSF-1. Sixteen hours later,
total cellular RNA was isolated, cDNAs were prepared, and levels of TLR9
mRNA relative to HPRT were estimated by quantitative PCR (n  3 
SD). Results are representative of two experiments. B, cDNAs were pre-
pared as in A, and levels of TLR1, 2, 4, 5, and 6 relative to HPRT were
determined. Data from two experiments were pooled, and results (n  6 
SEM) are expressed as fold repression in response to CSF-1. C, BMMs
were pretreated overnight with medium or CSF-1 (5  104 U/ml) and
then stimulated for 24 h with LPS (10 ng/ml), AO-1 (3 M), or
Pam3CysSerLys4 (10 ng/ml). IL-6 levels in culture supernatants were as-
sessed by ELISA (mean of triplicates SD). Similar results were obtained
in two experiments.
FIGURE 9. Regulation of TLR9 expression in macrophages. A, BMMs
were treated for 18 h with medium, CSF-1 (5  104 U/ml), IL-3 (103
U/ml), or PMA (100 ng/ml). Total RNA was prepared and levels of TLR9
and HPRT mRNA were assessed by PCR/Southern hybridization. B,
BMMs were starved of CSF-1 overnight and then treated with CSF-1 (5 
104 U/ml) for the indicated times. Expression levels of TLR9 and HPRT
were assessed as in A. C, TEPMs were cultured for 20 h with CSF-1 (5 
104 U/ml) or medium alone. Levels of TLR9, TLR4, and HPRT mRNAs
were estimated by PCR/Southern hybridization in total RNA from these
cells. Similar results were obtained in two independent experiments.
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regulate IL-6 production in response to the TLR2 ligand
Pam3CysSerLys4 (Fig. 8C). This may be because the level of
down-regulation of these TLR family members by CSF-1 is not
sufficient to regulate responses to their ligands. Another possibility
is that stimulation with TLR2 agonists may up-regulate TLR2 ex-
pression, which can in turn overcome the suppressive effect of
CSF-1. In this respect, we have found that CpG DNA does up-
regulate TLR9 mRNA levels in BMMs, but only in the presence of
CSF-1 (data not shown), although this autocrine regulation is ap-
parently insufficent to overcome the suppressive effect of CSF-1 on
CpG DNA responses. It would be interesting to assess the effect of
TLR2 ligands on TLR2 expression in macrophages in the presence
and absence of CSF-1. Indeed, a variety of inflammatory stimuli,
including LPS, selectively up-regulated TLR2 but not TLR4 ex-
pression (36, 37). The differential regulation of TLR members im-
plies that, as in drosophila, different kinds of pathogens could elicit
different outcomes. In keeping with this view, Sing et al. have
reported that Gram-negative organisms induce IFN-, whereas
Gram-positive bacteria lack this activity (38).
Although the ability of CSF-1 to prime murine macrophage re-
sponses to LPS has previously been reported for IL-6 and TNF-
production (14, 15), its effect on LPS-induced IL-12 production
has not been documented. In the case of IL-6, synergy between
CSF-1 and LPS might be partially due to CSF-1-induced GM-CSF
production (39). We have not fully investigated the mechanism by
which CSF-1 augments LPS responses of BMMs. We did find that
CSF-1 did not affect levels of LPS-induced TNF- mRNA, despite
having a marked effect on TNF- protein secretion, implying that
posttranscriptional mechanisms are responsible for this effect. In
support of this, p38 phosphorylation and nuclear translocation of
NF-B in response to LPS were not altered by CSF-1 pretreatment.
In the case of IL-12, LPS-induced p40, but not p35, mRNA was
enhanced by CSF-1 priming. Whether the effect of CSF-1 on LPS-
induced IL-12 (p40) mRNA is due to enhanced transcription or
enhanced mRNA stability has not yet been investigated. One pos-
sibility is that CSF-1 and LPS synergize at the level of transcrip-
tion because CSF-1 triggers sustained phosphorylation and activa-
tion of Ets-2 (30) and Ets-2 is necessary for full activation of the
IL-12 promoter in response to LPS (40, 41).
The majority of our findings used BMMs as a primary macro-
phage model. We have found that TEPMs cultured ex vivo retain
responsiveness to LPS but lose responsiveness to CpG DNA. Be-
cause of this decline in CpG DNA responsiveness ex vivo, we have
been unable to address the effect of CSF-1 pretreatment on CpG
responses in TEPMs. Nonetheless, the low basal expression of
TLR9 in TEPMs was further down-regulated by overnight treat-
ment with CSF-1 (Fig. 9), implying that this phenomenon is likely
to occur with all CSF-1-responsive macrophage populations. In
summary, CSF-1 reprograms macrophage responses to different
microbial stimuli. To our knowledge, this is the first report of a
cytokine or growth factor that has differential effects on macro-
phage responses to LPS and CpG DNA, and it highlights the im-
portance of regulated expression of TLRs. Discordant regulation of
TLRs may underlie different toxicities of TLR agonists in vivo and
may have relevance for the role of CSF-1 during bacterial infec-
tions. Furthermore, CSF-1 and CSF-1R antagonists may enhance
the efficacy of CpG DNA in therapeutic strategies and/or increase
its toxicity in vivo.
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